We’re hiring! 📢 We're looking for a: ➕ Translational Immunologist Validate the key causal drivers behind immune-mediated disease using more realistic biological and computational models. Read more and apply here: www.linkedin.com/jobs/view/44...

We're hiring! 📢 ➕ Translational Systems Biologist ➕ Research Data Engineer You’ll join an international team that values participation & collaboration, where you’ll be able to actively shape decisions, culture, & strategy. Apply here ➡️ graph-therapeutics.jobs.personio.com?language=en

📢 Exciting news! Paris-based VC firm daphni has joined our investor syndicate, leading an additional $5M investment, with continued participation from SquareOne, Merantix Capital, & NAVEC Investment Management. This brings our total funding, including non-dilutive grant support, to over $10M.

Ahoj Prague! 🇨🇿 Desy Vallorani, Research Assistant at Graph, will be attending Autoimmunity 2026 from 14 - 17 May! As we continue to decode complex immune dysfunction at scale, we’re looking forward to discussing the latest breakthroughs in inflammatory and immune-mediated diseases. ➕✖️

We’re hiring! 📢 We are scaling up our wet lab capabilities and are looking for a Molecular Immunologist to join our team. Consider applying if you are someone who wants to interrogate and validate immune-mediated disease drivers. 🧬🔍🥼 Read the full job description ➡️ lnkd.in/dX6jUgpN

Meet the team behind Graph and say hello to @benhaladik.bsky.social, Scientist! 🧗🛹 With Ben’s help, we’re combining live patient cell models with advanced machine learning to decode complex immune dysfunction, driving our lab-in-the-loop platform. ➕✖️

We're hiring! 📢 Our team is looking for a Full Stack Biologist driving research at the interface of computational & lab biology. Consider applying if you want to better understand the causal mechanisms of disease using multi-modal, realistic primary cell models. ⚙️ 🧬 💡 Apply here ➡️ lnkd.in/dBuA73nG

Today's rheumatoid arthritis (RA) therapies only slow disease. The next generation needs to cure it, and that first requires a comprehensive map of immune dysfunction. At IMMUNOLOGY2026, Graph's co-founder & VP Immunology Christophe Boudesco presented the latest results from our platform FIM. 🏗️ ⚙️

Attending IMMUNOLOGY2026? Stop by the Parse x Graph happy hour to talk science & to celebrate our joint partnership to create one of the largest & most comprehensive immune cell perturbation atlases. 🧬🔍 📆 16 April 2026, 19:00 📍 Trillium Brewing Fort Point 🎟️ RSVP: lnkd.in/d7sbWbEA

Hey Boston, we’ll be attending #IMMUNOLOGY2026 from 16 - 19 April! Connect with us over our work in immune dysfunction mapping for next generation drug discovery in rheumatoid arthritis.

Join us for a guest talk with @psl-schaefer.bsky.social (@saezlab.bsky.social, Uni Heidelberg)! 💬 Machine Learning for Cellular Perturbations at Scale: Current Capabilities, Limits, and Open Questions 📆 17 March 2026, 13:30 - 14:30 📍 LBI NetMed, Julius-Tandler-Platz 3, Top 5.1, 1090 Vienna

Meet the team behind Graph and say hello to Rin Okumura, Senior Scientist! 🧗⛷️ With Rin on the team, we’re scaling lab-in-the-loop discovery by translating complex biology to high-throughput automated workflows. ➕✖️

New look, same mission. 🧑‍🚀 🚀 We’re excited to debut our updated website that reflects who we are and the work we are doing at Graph: unafraid and boldly confronting the dynamic behavior of immune biology head on. Check it out 🌐 www.graphtx.com

In our latest talk & poster presentation at the Keystone Autoimmunity & Autoinflammation symposium, Graph’s co-founder & CSO Bojan Vilagos presented our generalizable & scalable approach for discovering shared mechanisms across disease contexts. 🧬 ⚙️ Full poster here 👉 graphtx.com/inflammasome...

Parse Biosciences and Graph are partnering to create the world's most comprehensive immune cell perturbation atlas aimed at revealing immune system dysfunction for curative drug discovery. 🧬 🗺️ ➡️ Read more: www.parsebiosciences.com/news/parse-b...

Fantastic panel at the Evotec Breakfast Reception in SF! Graph co-founder @gregvladimer.bsky.social shared insights alongside leaders from @isomorphiclabs.bsky.social & @medra-ai.bsky.social about how AI helps to unlock disease mechanisms & supports the development of future bio discoveries. 🚀

🏔️ Hey Colorado, we’ll be up in the Rockies from 19 - 22 January 2026 for the Autoimmunity & Autoinflammation symposium! We’re looking forward to showcasing our approach of using advanced imaging & data modeling to find clinically-relevant targets & pathways for immune diseases in our latest poster.

🌊 ⛵ Hey San Francisco, on 13 January 2026 adjacent to the 44th Annual JPM Healthcare Conference, Graph’s co-founder and CEO Greg Vladimer will be speaking on Evotec's panel “Precision at Scale: AI’s impact on Drug Discovery." Let us know if you are in San Francisco and let’s talk techbio!

Just last week, we had a group retreat (aka Graph Con) to a mountain hut in the Alps 🇦🇹. We spent some time honing our cooking skills, enjoying the wintry landscape, and forging our 2026 strategy around immune dysfunction mapping. We’re already energized for 2026, and we’re just getting started. 💫

Thank you to everyone who attended our AI x Bio meetup last week in Berlin! We had a great time catching up with old friends and making new connections. 🪩 🕺 👏 A huge thank you to all of our cohosts, including @Merantix AI Campus, Merantix Capital, CytoData, and @techbio.bsky.social support!

What does it takes to build real prediction power for precision immunology? Hint: it's about mapping immune dysfunction and scaling what's relevant. ➡️ Have a look at what we're building at Graph: graphtx.substack.com/p/building-t...

Building the Data Foundation to Scale Precision Immunology

Towards context-conditioned foundation models of immune dysfunction

graphtx.substack.com

Immune-mediated diseases are highly complex and heterogeneous, which makes the discovery of precision medicines difficult. In Graph’s most recent poster at #CytoData2025, our research team showcased our systematic approach to address this challenge. 🎯

Hey Berlin, we’ll be in town from 20 - 21 November for CytoData 2025! If you want to know more about how we are decoding the functional and molecular niche of immune-mediated diseases for iterative target discovery, come by our poster session to learn more!

Meet the team behind Graph and say hello to @izepb.bsky.social, Principal Scientist! 🧬⛰️ Ize is helping us scale new heights where ML meets biology, one complex system at a time. ➕✖️

​You’re invited to join us for an evening to connect with others building at the intersection of biology, technology, and AI: 📅 19 November 2025, 18:30 📍 Merantix AI Campus, Berlin 👉 Sign up: lu.ma/u4i3i1i3 We’re excited to see you there and to talk about the future of techbio with you! 💡⚙️

Berlin AI x Bio Meetup · Luma

Graph Therapeutics, Merantix Capital, and TechBio Transformers (TBT) are bringing together techbio enthusiasts and experts in Berlin for a meetup, timed…

lu.ma

✨ Some exciting news: We’re announcing a strategic partnership with the Botnar Institute of Immune Engineering (BIIE) to accelerate the development of precision medicines for immune-mediated diseases!

Meet the Graph team at #BIOEurope in Vienna from 3 - 5 November! We’ll be sharing how Graph is leading the way towards precision immunology drug discovery and development through capturing, mapping, and predicting patient immune dysfunction at scale.

Meet the team behind Graph and say hello to Desy Vallorani, Research Associate! 🚢🔬 With Desy’s help, we’re generating high-quality and contextually rich datasets for complex immune diseases. ➕✖️

Salut Lausanne 🇨🇭, Graph’s Senior Research Scientist Rin Okumura will be at the 2nd Symposium on the Immunobiology of Pattern Recognition Receptors hosted by @unil.bsky.social from 1 - 2 October! We’re excited to explore and discuss the latest discoveries in innate immune research. 💪 🧬

How can we best drive ideation, funding, and operation of academic-spin outs and academically linked ventures that span interdisciplinary fields, while keeping the end goal of patient success in mind? 💡⚙️